These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37715452)

  • 21. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New trials in resistant hypertension: mixed blessing stories.
    Zoccali C; Mallamaci F; De Nicola L; Minutolo R
    Clin Kidney J; 2024 Jan; 17(1):sfad251. PubMed ID: 38186891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging concepts for patients with treatment-resistant hypertension.
    Eirin A; Textor SC; Lerman LO
    Trends Cardiovasc Med; 2016 Nov; 26(8):700-706. PubMed ID: 27381561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of Hypertension in Chronic Dialysis Patients.
    Georgianos PI; Agarwal R
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):2062-2075. PubMed ID: 27797886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016.
    Epstein M; Duprez DA
    Am J Med; 2016 Jul; 129(7):661-6. PubMed ID: 26899747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension.
    Imprialos KP; Bouloukou S; Kerpiniotis G; Katsimardou A; Patoulias D; Bakogiannis C; Faselis C
    Curr Pharm Des; 2018; 24(46):5500-5507. PubMed ID: 30848188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.
    Sinnott SJ; Tomlinson LA; Root AA; Mathur R; Mansfield KE; Smeeth L; Douglas IJ
    Eur J Prev Cardiol; 2017 Feb; 24(3):228-238. PubMed ID: 27856806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone receptor antagonists for hypertension: what do they offer?
    Liew D; Krum H
    Drugs; 2003; 63(19):1963-72. PubMed ID: 12962513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
    J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.
    Oliveras A; Armario P; Clarà A; Sans-Atxer L; Vázquez S; Pascual J; De la Sierra A
    J Hypertens; 2016 Sep; 34(9):1863-71. PubMed ID: 27327441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and management of resistant hypertension.
    Camafort M; Kreutz R; Cho MC
    Heart; 2023 Dec; ():. PubMed ID: 38135468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone.
    Good ME; Chiu YH; Poon IKH; Medina CB; Butcher JT; Mendu SK; DeLalio LJ; Lohman AW; Leitinger N; Barrett E; Lorenz UM; Desai BN; Jaffe IZ; Bayliss DA; Isakson BE; Ravichandran KS
    Circ Res; 2018 Feb; 122(4):606-615. PubMed ID: 29237722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PURLs: Resistant hypertension? Time to consider this fourth-line drug.
    Kaysin A; Mounsey A
    J Fam Pract; 2016 Apr; 65(4):266-8. PubMed ID: 27262250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal denervation for resistant hypertension.
    Pisano A; Iannone LF; Leo A; Russo E; Coppolino G; Bolignano D
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD011499. PubMed ID: 34806762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of resistant hypertension: state of the art.
    Wei FF; Zhang ZY; Huang QF; Staessen JA
    Nat Rev Nephrol; 2018 Jul; 14(7):428-441. PubMed ID: 29700488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the management of secondary hypertension: chronic kidney disease.
    Masuda T; Nagata D
    Hypertens Res; 2020 Sep; 43(9):869-875. PubMed ID: 32555327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.